Taurine Blocks Joint Cartilage Destruction by Stopping Iron-Driven Cell Death
Taurine activates OGT/Gpx4 signaling to halt ferroptosis in chondrocytes, offering a safe dietary strategy against post-traumatic osteoarthritis.
Summary
Researchers used rat anterior cruciate ligament transection (ACLT) to model post-traumatic osteoarthritis (PTOA) and identified taurine as a key metabolite declining in OA progression. Combining metabolomics and transcriptomics, they found taurine protects chondrocytes by upregulating O-GlcNAc transferase (OGT), which stabilizes the ferroptosis-suppressing enzyme Gpx4 via O-GlcNAcylation—a post-translational modification that blocks Gpx4's ubiquitin-mediated degradation. Both cell-based and animal experiments confirmed that taurine supplementation reduces oxidative stress, lipid peroxidation, and cartilage destruction, suggesting that this safe, widely available amino acid could serve as a practical therapeutic or preventive strategy for sports-related joint injury.
Detailed Summary
Osteoarthritis (OA), particularly post-traumatic OA (PTOA) following anterior cruciate ligament (ACL) injury, lacks disease-modifying treatments. Affecting millions globally, PTOA results from a cascade of inflammation, oxidative stress, and chondrocyte death that progressively destroys cartilage. This study set out to identify novel metabolic and molecular mechanisms underlying PTOA and to explore whether taurine—an abundant, safe sulfur amino acid—could serve as a chondroprotective intervention.
Using the ACLT rat model, the researchers tracked cartilage degradation over 20 weeks via histological scoring (OARSI, Mankin), micro-CT, and toluidine blue staining, confirming progressive cartilage and subchondral bone deterioration. Chondrocyte and serum metabolomics using 1H NMR spectroscopy identified 37 metabolites; pathway enrichment (KEGG/MetaboAnalyst) highlighted taurine and hypotaurine metabolism as among the most significantly altered pathways. Notably, chondrocyte taurine declined at 4 weeks post-ACLT, rebounded at 8 weeks, while serum taurine showed the inverse pattern—consistent with a compensatory feedback mechanism. Serum taurine was also significantly lower in OA patients (n=25, mean age 65) versus healthy age-matched controls (n=30), reinforcing clinical relevance.
Integrated transcriptomics and metabolomics of IL-1β-treated chondrocytes revealed two converging pathways: OGT-dependent O-GlcNAcylation and Gpx4-dependent ferroptosis. Taurine treatment restored Gpx4 expression, reduced lipid ROS accumulation, and decreased ferroptosis markers (PTGS2, MDA, 4-HNE) while elevating antioxidant enzymes (SOD-2, CAT, HO-1). Gain- and loss-of-function experiments using OGT overexpression, OGT knockdown, the OGT inhibitor OSMI-1, and the OGA inhibitor Thiamet-G confirmed that OGT activity is required for taurine's protective effects. Crucially, co-immunoprecipitation and molecular docking identified a direct protein–protein interaction between OGT and Gpx4, and O-GlcNAcylation of Gpx4 was verified biochemically. Ubiquitination assays demonstrated that OGT-mediated O-GlcNAcylation reduces proteasomal degradation of Gpx4, thereby stabilizing it—a novel mechanistic finding.
In vivo validation employed adeno-associated virus (AAV)-mediated OGT overexpression or knockdown in ACLT rats, alongside intra-articular administration of taurine, OSMI-1, or Thiamet-G. AAV-OGT overexpression mimicked taurine's cartilage-protective effects, while OGT knockdown or OSMI-1 blocked taurine's benefits. Histological and micro-CT outcomes confirmed that the OGT/Gpx4 axis mediates taurine's chondroprotective action in vivo. This study is the first to report OGT-dependent O-GlcNAcylation as a regulatory mechanism in OA both in vitro and in vivo, and the first to document a direct OGT–Gpx4 interaction linking O-GlcNAcylation to ferroptosis suppression.
These findings position taurine supplementation—already recognized as safe and widely consumed—as a plausible preventive or therapeutic strategy for PTOA, particularly in athletes at risk of ACL injury. The OGT/Gpx4 axis also emerges as a novel druggable target for OA.
Key Findings
- Taurine levels drop in OA chondrocytes and serum of human OA patients, implicating it as a disease-relevant metabolite.
- Taurine suppresses chondrocyte ferroptosis by upregulating OGT, which stabilizes Gpx4 via O-GlcNAcylation.
- OGT directly binds Gpx4 and its O-GlcNAc modification reduces Gpx4 ubiquitin-mediated proteasomal degradation.
- AAV-mediated OGT overexpression in ACLT rats recapitulates taurine's cartilage-protective effects in vivo.
- This is the first study to establish OGT-dependent O-GlcNAcylation as a regulatory mechanism in OA in vivo.
Methodology
Rat ACLT model was used for in vivo PTOA induction; chondrocyte and serum metabolomics (1H NMR) plus transcriptomics identified taurine and OGT/Gpx4 as key targets. Mechanistic validation used cell transfection, small-molecule inhibitors (OSMI-1, Thiamet-G), co-IP, ubiquitination assays, and intra-articular AAV delivery in rats.
Study Limitations
Metabolomic data were unavailable for later ACLT timepoints (16–20 weeks) due to insufficient chondrocyte yield, creating a gap in longitudinal metabolic profiling. The human cohort was small (n=55) and cross-sectional, limiting causal inference. All in vivo mechanistic work was conducted in rodents, and translation to humans requires further validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.